SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "swepub ;lar1:(umu);pers:(Stattin Pär)"

Sökning: swepub > Umeå universitet > Stattin Pär

  • Resultat 1-10 av 179
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Varenhorst, Eberhard, et al. (författare)
  • The National Prostate Cancer Register in Sweden 1998-2002 : trends in incidence, treatment and survival
  • 2005
  • Ingår i: Scandinavian Journal of Urology and Nephrology. - 0036-5599. ; 39:2, s. 117-23
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To provide a descriptive review of the establishment of the National Prostate Cancer Register (NPCR) in Sweden, to present clinical characteristics at diagnosis and to calculate the relative survival of different risk groups after 5 years. MATERIAL AND METHODS: Since 1998, data on all newly diagnosed prostate cancers, including TNM classification, grade of malignancy, prostate-specific antigen (PSA) level and treatment, have been prospectively collected. For the 35,223 patients diagnosed between 1998 and 2002, relative survival in different risk groups has been calculated. RESULTS: Between 1998 and 2002, 96% of all prostate cancer cases diagnosed in Sweden were registered in the NPCR. The number of new cases increased from 6137 in 1998 to 7385 in 2002. The age-standardized rate rose in those aged < 70 years, while it was stable, or possibly declining from 1999, in the older age groups. The proportion of T1c tumours increased from 14% to 28% of all recorded cases. The age-adjusted incidence of advanced tumours (M1 or PSA > 100 ng/ml) decreased by 17%. The proportion of patients receiving curative treatment doubled. Patients with N1 or M1 disease or poorly differentiated tumours (G3 or Gleason score 8-10) had a markedly reduced relative 5-year survival rate. CONCLUSIONS: It is possible to establish a nationwide prostate cancer register including basic data for assessment of the disease in the whole of Sweden. The introduction of PSA screening has increased the detection of early prostate cancer in younger men and, to a lesser extent, decreased the incidence of advanced disease. The effect of these changes on mortality is obscure but the NPCR in Sweden will serve as an important tool in such evaluation.
  •  
2.
  • Bratt, Ola, et al. (författare)
  • Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer
  • 2015
  • Ingår i: European Urology. - 0302-2838. ; 68:1, s. 53-58
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive radical treatment, despite the high mortality associated with conservative management. Objective: To investigate how age and comorbidity affect treatment of men with HRnMPCa. Design, setting, and participants: This was an observational nationwide register study during 2001-2012. We identified 19 190 men of <80 yr of age diagnosed with HRnMPCa in the National Prostate Cancer Register of Sweden and 95 948 age-matched men without prostate cancer in the register of the total population. Outcome measurements and statistical analysis: The outcome was the proportion of men with HRnMPCa receiving radical treatment (radical prostatectomy or radiotherapy). Vital status and the Charlson comorbidity index (CCI) were obtained from nationwide registers. The 10-yr survival of men without prostate cancer, stratified by age and CCI, was used as a measure of the life expectancy of the men with prostate cancer. Results and limitations: The proportions receiving radical treatment varied with life expectancy among men younger than 70 yr, whereas use of these treatments did not match the long life expectancy of men in their seventies with CCI 0-1. Only 10% of men aged 75-80 yr with CCI 0 received radical treatment despite 52% probability of 10-yr life expectancy, compared with approximately half of the men younger than 70 yr with a similar life expectancy. The use of radical treatment for HRnMPCa increased with time in all Swedish counties, but a threefold difference between counties remained in 2009-2012 for patients aged 70-80 yr with CCI 0-1. Uncertain external validity is a study limitation, and the impact of physician versus patient preferences on treatment selection could not be assessed. Conclusions: Otherwise healthy men in their seventies with HRnMPCa were less likely to receive radical treatment than younger men with a similar life expectancy, although increasing use of radical treatment was observed during the study period. Our findings highlight the need for improved methods for clinical decision-making, including improved assessment of life expectancy. Patient summary: We performed a nationwide register study that showed that many healthy men in their seventies live for at least another 10 yr. Despite this long life expectancy, men in their seventies with high-risk nonmetastatic prostate cancer were often not treated with radical prostatectomy or radiotherapy, possibly because their life expectancy was underestimated. Our study highlights the need for improved clinical decision-making, which should incorporate an assessment of the patient's life expectancy.
3.
  • Van Hemelrijck, Mieke, et al. (författare)
  • Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer : Results From the Population-Based PCBaSe Sweden
  • 2010
  • Ingår i: Journal of Clinical Oncology. - 0732-183X. ; 28:21, s. 3448-3456
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose Cardiovascular disease (CVD) is a potential adverse effect of endocrine treatment (ET) for prostate cancer (PC). We investigated absolute and relative CVD risk in 76,600 patients with PC undergoing ET, curative treatment, or surveillance. Methods PCBaSe Sweden is based on the National Prostate Cancer Register, which covers more than 96% of PC cases. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of ischemic heart disease (IHD), acute myocardial infarction (MI), arrhythmia, heart failure, and stroke were calculated to compare observed and expected (using total Swedish population) numbers of CVD, taking into account age, calendar time, and previous CVD. Results Between 1997 and 2007, 30,642 patients with PC received primary ET, 26,432 curative treatment, and 19,527 surveillance. SIRs for CVD were elevated in all men with the highest for those undergoing ET, independent of circulatory disease history (SIR MI for men without circulatory disease history: 1.40 [95% CI, 1.31 to 1.49], 1.15 [95% CI, 1.01 to 1.31], and 1.20 [95% CI, 1.11 to 1.30] for men undergoing ET, curative treatment, and surveillance, respectively). Absolute risk differences (ARD) showed that two (arrhythmia) to eight (IHD) extra cases of CVD would occur per 1,000 person-years. SMRs showed similar patterns, with ARD of zero (arrhythmia) to three (IHD) per 1,000 person-years. Conclusion Increased relative risks of nonfatal and fatal CVD were found among all men with PC, especially those treated with ET. Because ET is currently the only effective treatment for metastatic disease and the ARDs were rather small, our findings indicate that CVD risk should be considered when prescribing ET but should not constitute a contraindication when the expected gain is tangible.
  •  
4.
  • Bratt, Ola, et al. (författare)
  • Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates.
  • 2010
  • Ingår i: Journal of the National Cancer Institute. - 1460-2105. ; 102, s. 1336-1343
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Family history is a strong risk factor for prostate cancer. The aim of this study was to investigate whether increased diagnostic activity is related to the incidence of prostate cancer among brothers of men with prostate cancer. Methods Data were from the nationwide population-based Prostate Cancer Database Sweden (PCBaSe Sweden), which includes data from the National Prostate Cancer Register, the Swedish Cancer Register, the Register of the Total Population, the Multi-Generation Register, and the Census database. We investigated the relationship of tumor characteristics, time from diagnosis of the index patient (ie, prostate cancer patients in the National Prostate Cancer Register for whom at least one brother and their father could be identified), calendar period, geographic factors, and socioeconomic status to standardized incidence ratios (SIRs) for prostate cancer among 22 511 brothers of 13 975 index patients in PCBaSe Sweden. Results Brothers of index patients with prostate cancer were at increased risk for a diagnosis of prostate cancer (SIR = 3.1, 95% confidence interval [CI] = 2.9 to 3.3). Risk was higher for T1c tumors (SIR = 3.4, 95% CI = 3.2 to 3.8) than for metastatic tumors (SIR = 2.0, 95% CI = 1.5 to 2.6), and risk of T1c tumors was especially high during the first year after the diagnosis of the index patient (SIR = 4.3, 95% CI = 3.8 to 4.9), compared with the following years (SIR range = 2.8-3.3), and for brothers of index patients who had a higher socioeconomic status (SIR = 4.2, 95% CI = 3.7 to 4.7), compared with brothers of index patients with lower socioeconomic status (SIR = 2.8, 95% CI = 2.4 to 3.2). Conclusions Increased diagnostic activity among men with a family history of prostate cancer appears to contribute to their increased risk of prostate cancer and to lead to detection bias in epidemiological and genetic studies of familial prostate cancer.
  •  
5.
  • Bratt, Ola, et al. (författare)
  • Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer.
  • 2015
  • Ingår i: BJU International. - Wiley-Blackwell Publishing. - 1464-4096 .- 1464-410X. ; 116:2, s. 213-219
  • Tidskriftsartikel (refereegranskat)abstract
    • To investigate how much Gleason pattern 3 cancer the prostate biopsy specimens may contain without an increased risk of undetected more aggressive cancer, compared with the risk for cancers fulfilling the National Comprehensive Cancer Network (NCCN) criteria for very low risk prostate cancer.
  •  
6.
  • Klein, Robert J, et al. (författare)
  • Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer.
  • 2010
  • Ingår i: Cancer Prevention Research. - 1940-6215 .- 1940-6207. ; May 4, s. 611-619
  • Tidskriftsartikel (refereegranskat)abstract
    • Polymorphisms associated with prostate cancer include those in three genes encoding major secretory products of the prostate: KLK2 (encoding kallikrein-related peptidase 2; hK2), KLK3 (encoding prostate-specific antigen; PSA), and MSMB (encoding beta-microseminoprotein). PSA and hK2, members of the kallikrein family, are elevated in sera of men with prostate cancer. In a comprehensive analysis that included sequencing of all coding, flanking, and 2 kb of putative promoter regions of all 15 kallikrein (KLK) genes spanning approximately 280 kb on chromosome 19q, we identified novel single-nucleotide polymorphisms (SNP) and genotyped 104 SNPs in 1,419 cancer cases and 736 controls in Cancer Prostate in Sweden 1, with independent replication in 1,267 cases and 901 controls in Cancer Prostate in Sweden 2. This verified prior associations of SNPs in KLK2 and in MSMB (but not in KLK3) with prostate cancer. Twelve SNPs in KLK2 and KLK3 were associated with levels of PSA forms or hK2 in plasma of control subjects. Based on our comprehensive approach, this is likely to represent all common KLK variants associated with these phenotypes. A T allele at rs198977 in KLK2 was associated with increased cancer risk and a striking decrease of hK2 levels in blood. We also found a strong interaction between rs198977 genotype and hK2 levels in blood in predicting cancer risk. Based on this strong association, we developed a model for predicting prostate cancer risk from standard biomarkers, rs198977 genotype, and rs198977 x hK2 interaction; this model had greater accuracy than did biomarkers alone (area under the receiver operating characteristic curve, 0.874 versus 0.866), providing proof in principle to clinical application for our findings. Cancer Prev Res; 3(5); 611-9. (c)2010 AACR.
  •  
7.
  •  
8.
  • Stattin, Pär, et al. (författare)
  • Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
  • 2010
  • Ingår i: Journal of the National Cancer Institute. - 1460-2105. ; 102:13, s. 950-8
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:Treatment for localized prostate cancer remains controversial. To our knowledge, there are no outcome studies from contemporary population-based cohorts that include data on stage, Gleason score, and serum levels of prostate-specific antigen (PSA).METHODS:In the National Prostate Cancer Register of Sweden Follow-up Study, a nationwide cohort, we identified 6849 patients aged 70 years or younger. Inclusion criteria were diagnosis with local clinical stage T1-2 prostate cancer from January 1, 1997, through December 31, 2002, a Gleason score of 7 or less, a serum PSA level of less than 20 ng/mL, and treatment with surveillance (including active surveillance and watchful waiting, n = 2021) or curative intent (including radical prostatectomy, n = 3399, and radiation therapy, n = 1429). Among the 6849 patients, 2686 had low-risk prostate cancer (ie, clinical stage T1, Gleason score 2-6, and serum PSA level of <10 ng/mL). The study cohort was linked to the Cause of Death Register, and cumulative incidence of death from prostate cancer and competing causes was calculated.RESULTS:For the combination of low- and intermediate-risk prostate cancers, calculated cumulative 10-year prostate cancer-specific mortality was 3.6% (95% confidence interval [CI] = 2.7% to 4.8%) in the surveillance group and 2.7% (95% CI = 2.1% to 3.45) in the curative intent group. For those with low-risk disease, the corresponding values were 2.4% (95% CI = 1.2% to 4.1%) among the 1085 patients in the surveillance group and 0.7% (95% CI = 0.3% to 1.4%) among the 1601 patients in the curative intent group. The 10-year risk of dying from competing causes was 19.2% (95% CI = 17.2% to 21.3%) in the surveillance group and 10.2% (95% CI = 9.0% to 11.4%) in the curative intent group.CONCLUSION:A 10-year prostate cancer-specific mortality of 2.4% among patients with low-risk prostate cancer in the surveillance group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease.
  •  
9.
  • Tomic, Katarina, et al. (författare)
  • Evaluation of data quality in the National Prostate Cancer Register of Sweden
  • 2015
  • Ingår i: European Journal of Cancer. - 0959-8049. ; 51:1, s. 101-111
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Data in cancer quality registers are increasingly used for quality assurance, benchmarking, and research. MATERIALS AND METHODS: Data in the National Prostate Cancer Register (NPCR) of Sweden were evaluated for completeness, timeliness, comparability and validity. Completeness and timeliness were assessed by cross-linkage to the Swedish Cancer Register, comparability was examined by comparing registration routines in NPCR with national and international guidelines, and validity was assessed by re-abstraction of data from medical charts for 731 men diagnosed with prostate cancer (Pca) in 2009. Furthermore, data on treatment were validated by record linkage to the Swedish Patient Register and The Prescribed Drug Register. RESULTS: NPCR captured 98% of Pca cases in the Cancer Register and the mean value for completeness of the 48 evaluated variables was 90% (range 64-100%). Timeliness increased substantially from 2008 to 2012 with 95% of cases reported within 12months after diagnosis in 2012. NPCR complied with national and international coding routines. Overall, the agreement between original data and re-abstracted data from 731 charts was high. For example, the correlation between original and re-abstracted data was 1.00 for date of surgery, and 0.97 for serum levels of prostate specific antigen and exact agreement was 97% for Gleason score at biopsy, 83% for clinical local T stage and more than 95% of the androgen deprivation therapies registered in NPCR had a corresponding filled prescription. CONCLUSION: Record linkages with other data sources and re-abstraction of data showed that data quality in NPCR is high.
  •  
10.
  • Robinson, David, et al. (författare)
  • Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline Phosphatase
  • 2008
  • Ingår i: Journal of Urology. - 0022-5347. ; 179:1, s. 117-123
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: We determined how serial measurements of prostate specific antigen and alkaline phosphatase can be used to predict survival early in the course of hormone treated metastatic prostate cancer.Materials and Methods: The study was based on a prospective randomized trial of 915 patients with metastatic prostate carcinoma designed to compare parenteral estrogen (polyestradiol phosphate) vs total androgen blockade. We included 697 men who survived at least 6 months and had complete serial measurements of prostate specific antigen and alkaline phosphatase. Six models were constructed based on prostate specific antigen and alkaline phosphatase at start, and after 6 months of treatment, alkaline phosphatase flare and relative prostate specific antigen velocity. We constructed time dependent receiver operating characteristic curves with corresponding area under the curve to predict death from prostate cancer within 3 years.Results: The best variables to predict outcome were alkaline phosphatase at 6 months (AUC 0.79 for polyestradiol phosphate and 0.72 for total androgen blockade), alkaline phosphatase at baseline (AUC 0.70 for polyestradiol phosphate and total androgen blockade) and prostate specific antigen at 6 months (AUC 0.70 for polyestradiol phosphate and total androgen blockade). Prostate specific antigen and alkaline phosphatase levels 6 months after start of treatment give better prediction of survival than baseline levels.Conclusions: Alkaline phosphatase at start of treatment and alkaline phosphatase and prostate specific antigen after 6 months can be used to predict survival of hormone treated metastatic prostate cancer.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 179
Åtkomst
fritt online (32)
Typ av publikation
tidskriftsartikel (165)
annan publikation (9)
forskningsöversikt (3)
konferensbidrag (1)
recension (1)
Typ av innehåll
refereegranskat (151)
övrigt vetenskapligt (26)
populärvet., debatt m.m. (2)
Författare/redaktör
Hallmans, Göran (45)
Kaaks, Rudolf (38)
Bergh, Anders, (31)
Garmo, Hans (30)
Holmberg, Lars, (22)
visa fler...
Wikström, Pernilla, (22)
Riboli, Elio (21)
Robinson, David, (21)
Johansson, Mattias (18)
Van Hemelrijck, Miek ... (18)
Rinaldi, Sabina (17)
Lukanova, Annekatrin (16)
Loeb, Stacy, (15)
Tumino, Rosario (14)
Adolfsson, Jan (14)
Allen, Naomi E. (14)
Bueno-de-Mesquita, H ... (14)
Jonsson, Håkan (14)
Lambe, Mats (13)
Stocks, Tanja (13)
Häggström, Christel (13)
Folkvaljon, Yasin, (13)
Key, Timothy J (12)
Björge, Tone (12)
Overvad, Kim (11)
Boeing, Heiner (11)
Manjer, Jonas (11)
Khaw, Kay-Tee (11)
Egevad, Lars (11)
Bratt, Ola (11)
Palli, Domenico (11)
Trichopoulos, Dimitr ... (11)
Travis, Ruth C (11)
Trichopoulou, Antoni ... (10)
Larrañaga, Nerea (10)
Tretli, Steinar (10)
Ulmer, Hanno (10)
Engeland, Anders (10)
Lundin, Eva, (9)
Nagel, Gabriele (9)
Appleby, Paul N. (9)
Selmer, Randi (9)
Concin, Hans (9)
Krogh, Vittorio (8)
Chirlaque, Maria-Dol ... (8)
Lenner, Per, (8)
Widmark, Anders (8)
Biessy, Carine (8)
Tjonneland, Anne (7)
visa färre...
Lärosäte
Uppsala universitet (49)
Karolinska Institutet (30)
Lunds universitet (26)
Göteborgs universitet (8)
Linköpings universitet (3)
visa fler...
Örebro universitet (1)
Sveriges Lantbruksuniversitet (1)
Högskolan Kristianstad (1)
visa färre...
Språk
Engelska (165)
Svenska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (138)
Lantbruksvetenskap (2)
Naturvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy